NuVasive Inc
F:NK8
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
N
|
NuVasive Inc
F:NK8
|
1.9B EUR |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
195.6B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
178.9B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
145.2B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
124.8B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
110.6B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
47.2B EUR |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
52.7B USD |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
50.9B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
46.3B USD |
Loading...
|
|
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
38.3B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
NuVasive Inc
Glance View
In the ever-evolving world of healthcare innovation, NuVasive Inc. stands as a noteworthy beacon in the field of spinal surgery technology. Founded in 1997 and based in San Diego, California, the company has carved a niche for itself with its minimally invasive surgical procedures designed to transform spinal care. The cornerstone of its success lies in its proprietary Maximum Access Surgery (MAS) platform, which reduces operating time and recovery periods for patients undergoing spinal procedures. By integrating its cutting-edge surgical solutions with advanced neuromonitoring technology and a comprehensive suite of procedural systems, NuVasive aids surgeons in executing complex operations with precision and efficiency. This unique amalgamation of technology and medical expertise not only enhances surgical outcomes but also has cemented NuVasive’s reputation as a leader in less-invasive spinal surgery. Financially, NuVasive harnesses an effective business model that generates revenue through the sale of its specialized surgical equipment, including implants and biologics, as well as through service offerings like its intraoperative monitoring services. The company's revenue streams are largely driven by product sales directly to hospitals and surgical centers, where innovative tools and technologies are in high demand. As healthcare facilities increasingly seek advanced methods to improve patient outcomes and operating efficiencies, NuVasive finds itself at the forefront of this demand, continuously expanding its product portfolio and global reach. By investing heavily in research and development, the company ensures its products stay at the cutting edge of medical technology, providing not just immediate financial growth, but also a long-term strategic advantage in the global market for spinal surgery solutions.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for NuVasive Inc is 71.7%, which is below its 3-year median of 71.7%.
Over the last 3 years, NuVasive Inc’s Gross Margin has increased from 70.6% to 71.7%. During this period, it reached a low of 69.4% on Dec 31, 2020 and a high of 72.5% on Sep 30, 2022.